Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2002

View Archived Issues

Celgene discusses product pipeline at investors conference

Myogen discusses top two products in pipeline

Gilead provides update on top three proprietary products

New indolinyl oxazolidinones compare favorably to linezolid in vitro and in vivo

Rosiglitazone as a novel therapy for ulcerative colitis

Analgesic effects demonstrated for sodium channel blockers in inflammatory pain model

Small-molecule compound discovered to block silencing protein

RTI compounds with improved anti-MAC activity compared to mefloquine

2-Hydroxyestradiol shows promise in the treatment of obesity and its sequelae

Enrollment completed for Axokine phase III obesity trial

Interferon Sciences explores cancer indications for Alferon N Injection

Enzon and Inhale enter broad strategic alliance

Hepatitis B vaccine candidate selected in Genencor/Epimmune collaboration

Corus licenses asthma technology from Mayo Clinic

Arimidex receives fast track designation for early breast cancer in postmenopausal women

Enrollment completed in phase II trial of pexelizumab in acute myocardial infarction

Prescient identifies development candidate for anxiety

North American marketing rights to Anoheal and Incostop acquired by Solvay

deCODE and Pharmacia form pharmacogenomics alliance in heart disease

Modulators of calcium-sensing receptors under study at CNRS

Nikken Chemicals describes new series of TNF-alpha production inhibitors

Antifungal compounds patented by Anadys

GSK claims new series of TPO mimetics

Diphenylmethane derivatives active as thyroid hormone receptor agonists

Antifungal agents from Lilly useful against Candida and Aspergillus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...